Vor Biopharma
59 hedge funds and large institutions have $128M invested in Vor Biopharma in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 17 increasing their positions, 17 reducing their positions, and 14 closing their positions.
143% more call options, than puts
Call options by funds: $17K | Put options by funds: $7K
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 17
0.08% less ownership
Funds ownership: 4.54% → 4.46% (-0.08%)
17% less funds holding
Funds holding: 71 → 59 (-12)
32% less capital invested
Capital invested by funds: $188M → $128M (-$60.1M)
86% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$169K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$92.1K |
| 3 |
Morgan Stanley
New York
|
+$83.5K |
| 4 |
ETC
Exchange Traded Concepts
Oklahoma City,
Oklahoma
|
+$47.1K |
| 5 |
SG Americas Securities
New York
|
+$46.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$442K |
| 2 |
Jane Street
New York
|
-$286K |
| 3 |
PL
Parkwood LLC
Cleveland,
Ohio
|
-$228K |
| 4 |
Millennium Management
New York
|
-$194K |
| 5 |
BlackRock
New York
|
-$157K |
VOR Hedge Fund Activity: Q3 2023 in Review
59 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Vor Biopharma (VOR) for Q3 2023, worth a combined $128M — down 32% from $188M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of VOR and 2 opened new positions — a net loss of 12 holders — while 17 trimmed existing stakes and 17 added.
The largest buyer was Bridgeway Capital Management, adding an estimated $169K. The largest seller was Thrivent Financial for Lutherans, cutting an estimated $442K.
- 59 institutional investors held Vor Biopharma (VOR) as of Q3 2023, down from 71 in Q2 2023.
- Funds reported $128M of Vor Biopharma stock for Q3 2023, down 32% quarter-over-quarter.
- 2 funds opened new Vor Biopharma positions in Q3 2023 and 14 closed out, a net change of -12 holders.
- The largest Vor Biopharma buyer in Q3 2023 was Bridgeway Capital Management, an estimated $169K added.
- The largest Vor Biopharma seller in Q3 2023 was Thrivent Financial for Lutherans, an estimated $442K sold.
Based on aggregated 13F filings for Q3 2023.